(SCANS) Sickle Cell Anemia Neurodevelopmental Screening - Mentoring and Research in Patient Oriented Research

镰状细胞病（SCD）是一种遗传性溶血性贫血， 发育迟缓和认知缺陷。慢性贫血，低氧饱和度，睡眠- 呼吸紊乱、脑梗死和社会经济地位低下是 有临床意义的认知障碍然而，SCD可能是一种无形的残疾。 患者的发展没有进行常规筛查，缺陷可能无法诊断。早期 儿童时期是筛查延迟的最重要时间，因为儿童可以接受 以证据为基础的和联邦授权的资源，以补救发展之前，进入 学校如果没有这些资源，这一弱势群体很有可能陷入贫困。 学历，失业，入狱。当前的长期目标 该项目旨在帮助患有SCD的幼儿接受早期教育， 学术上的成功为此，金博士建议研究实施 患有SCD的幼儿的发育筛查，这是一个通常被忽视的人群。博士 King是镰状细胞病实施项目U01资助的首席研究员。 为患有SCD的青少年提供认知筛查和干预的联盟。她领导 一组血液学家，一个神经心理学家，一个社会心理学家，职业治疗师， 和实施科学家进行干预和研究的实施 科学成果，以"扩大"循证实践。她将利用这一既定的 基础设施，以完成以下目标：目标1。为了确定障碍和促进因素， 监测和筛查0 - 3岁SCD儿童的早期儿童发育， 目标2确定具体的实施战略，以解决障碍和促进因素 儿童早期发育筛查。结果将为适当的干预提供信息， 改善SCD儿童发育筛查。这项提案将加强金博士的 职业生涯，让她获得必要的技能，招聘，教育，并指导干部， 卫生专业人员专注于实施科学，以改善临床和教育 SCD的结果。金博士在指导学生、学员和初级学员方面有着悠久的历史。 教师来自多个科学学科，包括医学，公共卫生，心理学， 教育和职业治疗。她对指导特别感兴趣 她将继续这样做，以培养未来的领导人。

Sickle cell disease (SCD) is an inherited hemolytic anemia associated with under-recognized developmental delay and cognitive deficits. Chronic anemia, low oxygen saturations, sleep- disordered breathing, cerebral infarcts, and low socioeconomic status are risk factors for clinically significant cognitive impairments. However, SCD can be an invisible disability. Patients’ development is not routinely screened and deficits may remain undiagnosed. Early childhood is the most important time to screen for delays because children can receive evidence-based and federally mandated resources to remediate development before entering school. Without such resources, this vulnerable population has a high probability of poor academic attainment, unemployment, and incarceration. The long-term goal of the current project is to prepare young children with SCD for early childhood education and sustained academic success. To achieve this, Dr. King proposes to study the implementation of developmental screening of young children with SCD, a typically overlooked population. Dr. King is the principal investigator of a U01 grant in the Sickle Cell Disease Implementation Consortium to provide cognitive screening and intervention for adolescents with SCD. She leads a team of hematologists, a neuropsychologist, a social psychologist, occupational therapists, and implementation scientists to both conduct interventions and study the implementation science outcomes in order to “scale up” evidence-based practices. She will use this established infrastructure to complete the following aims: Aim 1. To determine the barriers and facilitators of surveillance and screening of early childhood development of children with SCD age 0-3 years, and Aim 2. To identify specific implementation strategies to address the barriers and facilitators to early childhood development screening. The results will inform the appropriate intervention to improve developmental screening in children with SCD. This proposal will enhance Dr. King’s career by allowing her to gain the necessary skills to recruit, educate, and mentor a cadre of health professionals focused on implementation science for improving clinical and educational outcomes in SCD. Dr. King has a long track record of mentoring students, trainees, and junior faculty from multiple scientific disciplines including medicine, public health, psychology, education, and occupational therapy. She has a particular interest in mentoring underrepresented minorities, and she will continue to do so to develop future leaders.